HC Wainwright Has Negative Estimate for AVDL Q2 Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities researchers at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a report released on Tuesday, March 4th. HC Wainwright analyst O. Livnat now anticipates that the company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $1.44 EPS, FY2028 earnings at $1.54 EPS and FY2029 earnings at $1.83 EPS.

A number of other equities analysts have also issued reports on the company. Piper Sandler lowered their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft began coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $12.00 price target for the company. UBS Group dropped their price objective on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a research note on Monday, March 3rd. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Avadel Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Stock Performance

Shares of Avadel Pharmaceuticals stock opened at $7.91 on Friday. The company has a market capitalization of $762.22 million, a P/E ratio of -10.01 and a beta of 1.57. Avadel Pharmaceuticals has a 1 year low of $7.39 and a 1 year high of $19.09. The company’s fifty day moving average is $8.57 and its two-hundred day moving average is $11.37.

Insider Activity

In other news, Director Peter J. Thornton bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $8.04 per share, with a total value of $80,400.00. Following the purchase, the director now owns 104,055 shares of the company’s stock, valued at $836,602.20. This trade represents a 10.63 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Geoffrey Michael Glass purchased 20,279 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of $9.84 per share, for a total transaction of $199,545.36. Following the completion of the purchase, the director now directly owns 75,904 shares in the company, valued at $746,895.36. The trade was a 36.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 42,981 shares of company stock worth $400,005 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Wealth Effects LLC raised its holdings in shares of Avadel Pharmaceuticals by 4.9% during the 4th quarter. Wealth Effects LLC now owns 2,344,130 shares of the company’s stock valued at $24,637,000 after buying an additional 110,359 shares during the period. XTX Topco Ltd acquired a new position in Avadel Pharmaceuticals during the 3rd quarter valued at approximately $642,000. State Street Corp grew its position in shares of Avadel Pharmaceuticals by 42.5% during the third quarter. State Street Corp now owns 1,623,302 shares of the company’s stock worth $21,290,000 after acquiring an additional 483,787 shares during the last quarter. SG Americas Securities LLC grew its position in Avadel Pharmaceuticals by 274.6% in the 4th quarter. SG Americas Securities LLC now owns 46,767 shares of the company’s stock worth $492,000 after purchasing an additional 34,281 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of Avadel Pharmaceuticals by 45.8% in the third quarter. Barclays PLC now owns 392,691 shares of the company’s stock valued at $5,150,000 after purchasing an additional 123,430 shares during the period. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.